The European Cancer Pulse: tracking inequalities in cancer control for citizen benefit

Norbert Couespel; Enea Venegoni; Mark Lawler

doi:10.1016/S1470-2045(23)00140-7

The European Cancer Pulse: tracking inequalities in cancer control for citizen benefit

Norbert Couespel^*, Enea Venegoni, Mark Lawler

^*Corresponding author for this work

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Comment/debate › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	441-442
Number of pages	2
Journal	Lancet Oncology
Volume	24
Issue number	5
DOIs	https://doi.org/10.1016/S1470-2045(23)00140-7
Publication status	Published - 01 May 2023

Keywords

Europe - epidemiology
Socioeconomic Factors
Humans
Neoplasms - diagnosis - epidemiology - therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(23)00140-7Licence: Unspecified

Cite this

@article{1d90ec9df02e4adba293579787d7b7a9,

title = "The European Cancer Pulse: tracking inequalities in cancer control for citizen benefit",

keywords = "Europe - epidemiology, Socioeconomic Factors, Humans, Neoplasms - diagnosis - epidemiology - therapy",

author = "Norbert Couespel and Enea Venegoni and Mark Lawler",

year = "2023",

month = may,

day = "1",

doi = "10.1016/S1470-2045(23)00140-7",

language = "English",

volume = "24",

pages = "441--442",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "5",

}

TY - JOUR

T1 - The European Cancer Pulse: tracking inequalities in cancer control for citizen benefit

AU - Couespel, Norbert

AU - Venegoni, Enea

AU - Lawler, Mark

PY - 2023/5/1

Y1 - 2023/5/1

KW - Europe - epidemiology

KW - Socioeconomic Factors

KW - Humans

KW - Neoplasms - diagnosis - epidemiology - therapy

U2 - 10.1016/S1470-2045(23)00140-7

DO - 10.1016/S1470-2045(23)00140-7

M3 - Comment/debate

C2 - 37142370

SN - 1470-2045

VL - 24

SP - 441

EP - 442

JO - Lancet Oncology

JF - Lancet Oncology

IS - 5

ER -